How does this company make money?
The company earns money three ways. It sells hip and knee implants directly to hospitals each time a procedure is performed. It sells the Mako robotic system itself as a large capital purchase. And it collects ongoing fees from hospitals for software licensing and maintenance of the robotic platform.
What makes this company hard to replace?
Training a surgical team to use the Mako system takes months, and that investment in time and muscle memory discourages switching. At the same time, hospitals manage their implant inventory through group purchasing organization contracts that become woven into supply chain systems — untangling those contracts and re-stocking with a competitor's implants is a slow, expensive process.
What limits this company?
Before any new implant size or shape can be added to the Mako system, the FDA requires clinical data proving it is safe and mechanically sound — a process called 510(k) clearance. That review cycle, not the speed of the company's manufacturing plants in Ireland, Michigan, or New Jersey, sets the pace at which the system can grow.
What does this company depend on?
The company cannot operate without cobalt-chromium and titanium alloy suppliers for making implants, the FDA 510(k) clearance pathway for approving each implant design, the Mako robotic software platform itself, hospital capital equipment budgets large enough to purchase robotic systems, and orthopedic surgeon training programs that certify surgeons to use the Mako system.
Who depends on this company?
Orthopedic surgeons performing hip and knee replacements rely on Mako for the robotic guidance that makes their cuts precise — without it, they would revert to freehand techniques. Hospital operating rooms built around Mako would need to find and integrate an entirely different surgical planning system. Patients who already have Mako-placed implants depend on the company remaining operational, because revision surgeries require access to the same implant components.
How does this company scale?
Once the Mako software and training protocols exist, they can be rolled out across additional hospital networks without rebuilding them from scratch each time. What does not scale automatically is access: hospital procurement committees make large capital decisions slowly, and surgeon relationships must be built one by one — neither can be shortcut by spending more money.
What external forces can significantly affect this company?
If Medicare lowers its reimbursement rates for joint replacement procedures, hospitals earn less per surgery and become less willing to spend on expensive robotic systems. On the other side, aging populations in developed countries are steadily increasing demand for hip and knee replacements. Medical device tax policies in both the United States and European markets can also raise or lower the effective price hospitals pay for implants and equipment.
Where is this company structurally vulnerable?
If the FDA moved robotic-guided orthopedic cutting systems from the current 510(k) approval route to the stricter PMA route — which requires large randomized clinical trials rather than showing similarity to an existing device — every implant geometry already in the Mako planning library would need to be re-approved. That would sever the connection between the surgical planning software and the bone-cutting system, destroying the closed loop that makes the platform distinctive.
CompanyGraph